Belgium vs Costa Rica: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Belgium
- Costa Rica
How they compare
Costa Rica currently reports 747.26 deaths against 636.61 deaths in Belgium, a difference of 110.65 deaths.
That makes Costa Rica's figure about 1.2 times Belgium's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Costa Rica ahead.
Belgium ranks 85th and Costa Rica ranks 83rd of 157 countries.
Across the 4 decades both report, Belgium averaged higher in 3 and Costa Rica in 1.
Head to head by decade
| Decade | Belgium | Costa Rica | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 99.54 deaths | 0 deaths | 99.54 deaths | Belgium |
| 2000s | 355.19 deaths | 162.78 deaths | 192.41 deaths | Belgium |
| 2010s | 595.22 deaths | 432.26 deaths | 162.96 deaths | Belgium |
| 2020s | 650.64 deaths | 675.17 deaths | 24.53 deaths | Costa Rica |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Belgium or Costa Rica?
- Costa Rica, at 747.26 deaths against 636.61 deaths in Belgium as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Belgium and Costa Rica?
- 110.65 deaths, with Costa Rica ahead.
- How many years of comparable data are there for Belgium and Costa Rica?
- 35 years are reported by both, from 1990 to 2024.
- How do Belgium and Costa Rica rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Belgium ranks 85th and Costa Rica ranks 83rd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.